RECOMBINANT CHIMERIC ACETYLCHOLINE RECEPTORS AND THEIR DERIVATIVES RECOGNIZED BY CD4 T CELLS OF MYASTHENIC PATIENTS FOR THE TREATMENT OF MYASTHENIA GRAVIS
    1.
    发明申请
    RECOMBINANT CHIMERIC ACETYLCHOLINE RECEPTORS AND THEIR DERIVATIVES RECOGNIZED BY CD4 T CELLS OF MYASTHENIC PATIENTS FOR THE TREATMENT OF MYASTHENIA GRAVIS 有权
    重组的乙酰胆碱受体及其由感染MYASTHENIA GRAVIS的MYASTHENIC患者的CD4T细胞识别的衍生物

    公开(公告)号:US20070072264A1

    公开(公告)日:2007-03-29

    申请号:US11421433

    申请日:2006-05-31

    CPC分类号: C07K14/4756

    摘要: The present invention relates to recombinant acetylcholine receptor polypeptides recognized by CD4 T cells of a myasthenia gravis patient and compositions for the treatment of myasthenia gravis containing the same as an effective ingredient, more precisely, recombinant acetylcholine receptor polypeptides deficient in B cell epitope, recombinant acetylcholine polypeptides in which two or more T cell epitopes are fused, a composition for the treatment of myasthenia gravis containing the above recombinant polypeptides as an effective ingredient and a treatment method for myasthenia gravis using the composition. The composition containing one or more recombinant polypeptides above can be effectively used as a myasthenia gravis specific therapeutic agent or immunomodulator without side effects.

    摘要翻译: 本发明涉及由重症肌无力患者的CD4T细胞识别的重组乙酰胆碱受体多肽和用于治疗重症肌无力的组合物,其含有与有效成分相同的重组乙酰胆碱受体多肽,更确切地说,是缺乏B细胞表位的重组乙酰胆碱受体多肽,重组乙酰胆碱 其中两个或多个T细胞表位融合的多肽,用于治疗含有上述重组多肽作为有效成分的重症肌无力的组合物和使用该组合物的重症肌无力治疗方法。 含有上述一种或多种重组多肽的组合物可以有效地用作重症肌无力特异性治疗剂或免疫调节剂而没有副作用。

    Recombinant chimeric acetylcholine receptors and their derivatives recognized by CD4 T cells of myasthenic patients for the treatment of myasthenia gravis
    3.
    发明授权
    Recombinant chimeric acetylcholine receptors and their derivatives recognized by CD4 T cells of myasthenic patients for the treatment of myasthenia gravis 有权
    由重症肌无力患者的CD4 T细胞识别的重组嵌合乙酰胆碱受体及其衍生物用于治疗重症肌无力

    公开(公告)号:US07777003B2

    公开(公告)日:2010-08-17

    申请号:US11421433

    申请日:2006-05-31

    IPC分类号: C07K14/705 C07K19/00

    CPC分类号: C07K14/4756

    摘要: The present invention relates to recombinant acetylcholine receptor polypeptides recognized by CD4 T cells of a myasthenia gravis patient and compositions for the treatment of myasthenia gravis containing the same as an effective ingredient, more precisely, recombinant acetylcholine receptor polypeptides deficient in B cell epitope, recombinant acetylcholine polypeptides in which two or more T cell epitopes are fused, a composition for the treatment of myasthenia gravis containing the above recombinant polypeptides as an effective ingredient and a treatment method for myasthenia gravis using the composition. The composition containing one or more recombinant polypeptides above can be effectively used as a myasthenia gravis specific therapeutic agent or immunomodulator without side effects.

    摘要翻译: 本发明涉及由重症肌无力患者的CD4T细胞识别的重组乙酰胆碱受体多肽和用于治疗重症肌无力的组合物,其含有与有效成分相同的重组乙酰胆碱受体多肽,更确切地说,是缺乏B细胞表位的重组乙酰胆碱受体多肽,重组乙酰胆碱 其中两个或多个T细胞表位融合的多肽,用于治疗含有上述重组多肽作为有效成分的重症肌无力的组合物和使用该组合物的重症肌无力治疗方法。 含有上述一种或多种重组多肽的组合物可以有效地用作重症肌无力特异性治疗剂或免疫调节剂而没有副作用。